Modeling the impact of real-world adherence to once-daily (QD) versus twice-daily (BID) non-vitamin K antagonist oral anticoagulants on stroke and major bleeding events among non-valvular atrial fibrillation patients

References

• Center for Desease Control and Prevention. Atrial Fibrillation Fact Sheet. Atlanta, GA: CDC; 2015. Available at: https://www.cdc.gov/dhdsp/data_statistics/fact_sheets/fs_atrial_fibrillation.htm. [Last accessed 8 September 2017]
   Google Scholar
• You JJ, Singer DE, Howard PA, et al. Antithrombotic therapy for atrial fibrillation: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012;141(2 Suppl):e531S-e575S
   PubMed Web of Science ®Google Scholar
• Miyasaka Y, Barnes ME, Gersh BJ, et al. Secular trends in incidence of atrial fibrillation in Olmsted County, Minnesota, 1980 to 2000, and implications on the projections for future prevalence. Circulation 2006;114:119-25
   PubMed Web of Science ®Google Scholar
• Go AS, Hylek EM, Phillips KA, et al. Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) study. JAMA 2001;285:2370-5
   PubMed Web of Science ®Google Scholar
• Markides V, Schilling RJ. Atrial fibrillation: classification, pathophysiology, mechanisms and drug treatment. Heart 2003;89:939-43
   PubMed Web of Science ®Google Scholar
• Enriquez A, Lip GY, Baranchuk A. Anticoagulation reversal in the era of the non-vitamin K oral anticoagulants. Europace 2016;18:955-64
   PubMed Web of Science ®Google Scholar
• January CT, Wann LS, Alpert JS, et al. 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society. 2014;64:e1-e76
   Google Scholar
• Ageno W, Gallus AS, Wittkowsky A, et al. Oral anticoagulant therapy: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest 2012;141(2 Suppl):e44S-e88S
   PubMed Web of Science ®Google Scholar
• Mekaj YH, Mekaj AY, Duci SB, et al. New oral anticoagulants: their advantages and disadvantages compared with vitamin K antagonists in the prevention and treatment of patients with thromboembolic events. Ther Clin Risk Manag 2015;11:967-77
   PubMed Web of Science ®Google Scholar
• US Food and Drug Administration (FDA). COUMADIN (warfarin sodium) - highlights of prescribing information. Silver Spring, MD: FDA; 2011. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/009218s107lbl.pdf [Last accessed 3 August 2017]
   Google Scholar
• Adam SS, McDuffie JR, Ortel TL, et al. Comparative effectiveness of warfarin and new oral anticoagulants for the management of atrial fibrillation and venous thromboembolism: a systematic review. Ann Intern Med 2012;157:796-807
   PubMed Web of Science ®Google Scholar
• Bellamy L, Rosencher N, Eriksson B. Adherence to a new oral anticoagulant treatment prescription: dabigatran etexilate. Patient Prefer Adherence 2009;3:173-7
   PubMed Web of Science ®Google Scholar
• Rodriguez RA, Carrier M, Wells PS. Non-adherence to new oral anticoagulants: a reason for concern during long-term anticoagulation? J Thromb Haemost 2013;11:390-4
   PubMed Web of Science ®Google Scholar
• Bae JP, Dobesh PP, Klepser DG, et al. Adherence and dosing frequency of common medications for cardiovascular patients. Am J Manag Care 2012;18:139-46
   PubMed Web of Science ®Google Scholar
• Coleman CI, Limone B, Sobieraj DM, et al. Dosing frequency and medication adherence in chronic disease. J Manag Care Pharm 2012;18:527-39
   PubMed Web of Science ®Google Scholar
• Doesch AO, Mueller S, Konstandin M, et al. Increased adherence after switch from twice daily calcineurin inhibitor based treatment to once daily modified released tacrolimus in heart transplantation: a pre-experimental study. Transplant Proc 2010;42:4238-42
   PubMed Web of Science ®Google Scholar
• Kardas P. Compliance, clinical outcome, and quality of life of patients with stable angina pectoris receiving once-daily betaxolol versus twice daily metoprolol: a randomized controlled trial. Vasc Health Risk Manag 2007;3:235-42
   PubMedGoogle Scholar
• Laliberte F, Bookhart BK, Nelson WW, et al. Impact of once-daily versus twice-daily dosing frequency on adherence to chronic medications among patients with venous thromboembolism. Patient 2013;6:213-24
   PubMedGoogle Scholar
• Laliberte F, Nelson WW, Lefebvre P, et al. Impact of daily dosing frequency on adherence to chronic medications among nonvalvular atrial fibrillation patients. Adv Ther 2012;29:675-90
   PubMed Web of Science ®Google Scholar
• Weeda ER, Coleman CI, McHorney CA, et al. Impact of once- or twice-daily dosing frequency on adherence to chronic cardiovascular disease medications: a meta-regression analysis. Int J Cardiol 2016;216:104-9
   PubMed Web of Science ®Google Scholar
• Claxton AJ, Cramer J, Pierce C. A systematic review of the associations between dose regimens and medication compliance. Clin Ther 2001;23:1296-310
   PubMed Web of Science ®Google Scholar
• Andrade JG, Krahn AD, Skanes AC, et al. Values and preferences of physicians and patients with nonvalvular atrial fibrillation who receive oral anticoagulation therapy for stroke prevention. Can J Cardiol 2016;32:747-53
   PubMed Web of Science ®Google Scholar
• Cunningham A, Stein CM, Chung CP, et al. An automated database case definition for serious bleeding related to oral anticoagulant use. Pharmacoepidemiol Drug Saf 2011;20:560-6
   PubMed Web of Science ®Google Scholar
• Nau DP. Proportion of days covered (PDC) as a preferred method of measuring medication adherence. Alexandria, VA; 2012. Available at: http://ep.yimg.com/ty/cdn/epill/pdcmpr.pdf [Last accessed 8 September 2017]
   Google Scholar
• Alberts MJ, Peacock WF, Fields LE, et al. Association between once- and twice-daily direct oral anticoagulant adherence in nonvalvular atrial fibrillation patients and rates of ischemic stroke. Int J Cardiol 2016;215:11-13
   PubMed Web of Science ®Google Scholar
• Brown JD, Shewale AR, Talbert JC. Adherence to rivaroxaban, dabigatran, and apixaban for stroke prevention in incident, treatment-naive nonvalvular atrial fibrillation. J Manag Care Spec Pharm 2016;22:1319-29
   PubMedGoogle Scholar
• Coleman C, Yuan Z, Schein J, et al. Importance of balancing follow-up time and impact of oral-anticoagulant users' selection when evaluating medication adherence in atrial fibrillation patients treated with rivaroxaban and apixaban. Curr Med Res Opin 2017;33:1033-43
   PubMed Web of Science ®Google Scholar
• Coleman CI, Tangirala M, Evers T. Medication adherence to rivaroxaban and dabigatran for stroke prevention in patients with non-valvular atrial fibrillation in the United States. Int J Cardiol 2016;212:171-3
   PubMed Web of Science ®Google Scholar
• Forslund T, Wettermark B, Hjemdahl P. Comparison of treatment persistence with different oral anticoagulants in patients with atrial fibrillation. Eur J Clin Pharmacol 2016;72:329-38
   PubMed Web of Science ®Google Scholar
• Maura G, Pariente A, Alla F, et al. Adherence with direct oral anticoagulants in nonvalvular atrial fibrillation new users and associated factors: a French nationwide cohort study. Pharmacoepidemiol Drug Saf 2017;26:1367–1377.
   PubMed Web of Science ®Google Scholar
• McHorney CA, Ashton V, Laliberte F, et al. Adherence to rivaroxaban compared with other oral anticoagulant agents among patients with nonvalvular atrial fibrillation. J Manag Care Spec Pharm 2017;23:980-8
   PubMed Web of Science ®Google Scholar
• McHorney CA, Crivera C, Laliberte F, et al. Adherence to non-vitamin-K-antagonist oral anticoagulant medications based on the Pharmacy Quality Alliance measure. Curr Med Res Opin 2015;31:2167-73
   PubMed Web of Science ®Google Scholar
• Shore S, Carey EP, Turakhia MP, et al. Adherence to dabigatran therapy and longitudinal patient outcomes: insights from the veterans health administration. Am Heart J 2014;167:810-17
   PubMed Web of Science ®Google Scholar
• Rozjabek HM, Coleman CI, Ashton V, et al. Healthcare costs of stroke and major bleeding among patients with atrial fibrillation treated with non-vitamin K antagonist oral anticoagulants. Academy of Managed Care Pharmacy (AMCP) Nexus 2017 Meeting, October 16–19. Dallas, TX; 2017
   Google Scholar
• Ashburner JM, Singer DE, Lubitz SA, et al. Changes in use of anticoagulation in patients with atrial fibrillation within a primary care network associated with the introduction of direct oral anticoagulants. Am J Cardiol 2017;120:786-91
   PubMed Web of Science ®Google Scholar
• Pokorney SD, Granger CB, Anstrom K, et al. Rates of oral anticoagulant use, while improving over time, remain low among hospitalized patients with atrial fibrillation. J Am Coll Cardiol 2017;69:363
   Web of Science ®Google Scholar
• Bansilal S, Castellano JM, Garrido E, et al. Assessing the impact of medication adherence on long-term cardiovascular outcomes. J Am Coll Cardiol 2016;68:789-801
   PubMed Web of Science ®Google Scholar
• Valgimigli M, Garcia Garcia H, Vrijens B, et al. Standardized classification and framework for reporting, interpreting, and analysing medication non-adherence in cardiovascular clinical trials: a consensus report from the Non-adherence Academic Research Consortium (NARC). Eur Heart J 2018
   Web of Science ®Google Scholar
• Bailey JE, Wan JY, Tang J, et al. Antihypertensive medication adherence, ambulatory visits, and risk of stroke and death. J Gen Intern Med 2010;25:495-503
   PubMed Web of Science ®Google Scholar
• Breekveldt-Postma NS, Penning-van Beest FJ, Siiskonen SJ, et al. The effect of discontinuation of antihypertensives on the risk of acute myocardial infarction and stroke. Curr Med Res Opin 2008;24:121-7
   PubMed Web of Science ®Google Scholar
• Casciano JP, Dotiwala ZJ, Martin BC, et al. The costs of warfarin underuse and nonadherence in patients with atrial fibrillation: a commercial insurer perspective. J Manag Care Pharm 2013;19:302-16
   PubMed Web of Science ®Google Scholar
• Goette A, Hammwöhner M. How important it is for therapy adherence to be once a day? Eur Heart J Suppl 2016;18(suppl_I):I7-I12
   Web of Science ®Google Scholar
• Vrijens B, Heidbuchel H. Non-vitamin K antagonist oral anticoagulants: considerations on once- vs. twice-daily regimens and their potential impact on medication adherence. Europace 2015;17:514-23
   PubMed Web of Science ®Google Scholar
• McHorney CA, Crivera C, Laliberté F, et al. Adherence to rivaroxaban versus apixaban among patients with non-valvular atrial fibrillation: analysis of overall population and subgroups of prior oral anticoagulant users. PLoS One 2018;13:e0194099
   PubMed Web of Science ®Google Scholar